When the Label Lags the Science: Using 505(o)(4) to Compel Labeling Changes August 13, 2026 By Sara W. Koblitz —

https://www.thefdalawblog.com/2026/08/when-the-label-lags-the-science-using-505o4-to-compel-labeling-changes/?utm_source=rss&utm_medium=rss&utm_campaign=when-the-label-lags-the-science-using-505o4-to-compel-labeling-changes When perusing regulations.gov, as bloggers searching for content are wont to do, we ran across an interesting Citizen Petition from June that grabbed our attention. Indeed, a June 11, 2026 Petition from Marc R. Matrana, M.D.—System Medical Director of Precision Medicine at the Ochsner MD Anderson Cancer Center in New Orleans and a longtime advocate for precision-oncology legislation in Louisiana—caught our eye because of the novel use of FDC Act § 505(o)(4). Typically reserved for when the Agency learns of new safety issues from adverse events or publications, FDC Act § 505(o)(4) allows FDA to request that a sponsor update its product labeling when the Agency “becomes aware of new information, including any new safety information or information related to reduced effectiveness, that [FDA] determines should be included in the labeling of the drug.” In other words, FDC Act § 505(o)(4) instructs FDA to initiate labeling changes once it becomes aware of new safety information, which can include effectiveness (FDA has interpreted the “effectiveness” issue to mean that if a drug’s ineffectiveness leads to death, risk of death, hospitalization, or incapacitation, it can be a basis for a mandated labeling change.). This Petition uses FDC Act § 505(o)(4) as a lever to force updated scientific information into labeling. It’s an interesting use of the regulatory procedure.